america
share
feedback manag investor lunch
quarter maintain outperform
better-than-expect cut dividend
updat allogen entri bcma car-t frenzi
deliv earli sign clinic activ
report follow-up confer call
updat seek proof-of-concept ipsc-nk
updat look ahead non-invas nash dynam
analyst certif import disclosur see
strong tug war outlook continu
review pipelin commerci execut continu pt
updat highlight progress sever front
continu progress
review focu sharpen pegasu near
report soft bill execut concern
solid execut advertis leverag impli traffic
profit initi track achiev medium-term margin
model report strong finish strategi appear
work rais pt
in-lin quarter revenu bottom
address focu sale execut
plenti move part fiscal maintain outperform
quick read ww set launch new product innov
sustain growth driver growth look sustain
takeaway manag meet
first look strong ebitda execut debt reduct
growth continu although incent incom slow patch
stabl quarter asset qualiti continu excel
share
share outperform-r wayfair struggl late market digest indic weaken top-lin
expans turn discern toward high-growth less-than-profit busi model review
care wayfair long-term posit call equiti share could remain penalti box longer
said key reason view busi model intact long-term prospect share compel
still impress top-lin growth apt rebound somewhat transitori pressur abat come quarter oper
leverag like improv invest spend eas share track consist recent trough
level price target share goe
feedback manag investor lunch
host manag chief commerci offic brian goff ir investor lunch boston
well-attend event wide rang investor posit surpris convict potenti
ultomiri across seven potenti franchis pnh ahu gmg nmosd hsct-tma al ppm compani
belief new cfo paul clanci depart cfo school thought term margin control non-
opex trifl concern around entri potenti biosimilar us ex-u market even
earli laser focu provid patient healthcar system qualiti medicin econom
quarter maintain outperform
gwph report revenu line estim higher consensu repres
sequenti growth estim new patient acquisit rate could reason near term note
grow number prescrib key driver new patient uptak gwph met top-line
expect lower epidiolex revenu estim futur period anticip moder new patient number
higher attrit rate lower price target maintain outperform rate continu
believ epidiolex use multipl seizur type fulli reflect stock current level
great mani analyst investor view bank total captiv macro cycl recent low interest rate
particular view interest rate independ variabl nim depend variabl whatev happen
result flow bottom line macro environ cours import may take time
adjust would argu long credit issu think bank actual good deal
flexibl manag reason return introduc notion four lever manag return report
think good time revisit loan deposit price underwrit standard deliveri cost equiti return
expect share under-perform wednesday deliv weak earn print give less effici
guidanc we/consensu expect soft earn print viper energi partner last week
modest expect diamondback play dramat expect print weak
realiz low oil cut higher expect cash unit expens drove big earn miss addit updat
guidanc came less effici expect term gener oil product
mb/d consensu understand issu drove weak frac interfer complet gassi
energen duc storm believ one-tim natur speak manag fact remain
messiest quarter rememb diamondback seven year public compani manag need
lay nuanc strateg outlook stem rel under-perform expect play call
better-than-expect cut dividend elimin stock dividend maintain perform
driven tobacco price less-than-expect declin estat ebitda beat
estim long-overdu move compani announc reduc quarterli dividend
share elimin long-stand annual stock dividend dividend cut initi caus pain put
compani better financi foot lower cost borrow make institut viabl invest
dividend longer well excess maintain perform
report adj ep toppingopco/street estim adj result exclud
il interest incom off-set sever stock-bas compens impress same-
store growth hh/hospic driven narrow network ny initi recoveri il
minimum-wag rate increas portion first tranch il still net headwind quarter due
addit wage hike compani still wait approv remaind increas immin though
conserv includ reflect updat assumpt rais ep estim
price target
updat allogen entri bcma car-t frenzi
tuesday allogen report result review recent progress call manag re-affirmed guidanc present
initi data alpha trial separ recent becam first allogen bcma-
target car-t enter clinic treatment r/r multipl myeloma phase studi enrol
patient receiv least three prior line therapi could deliv initi data late turn long
game allogen announc collabor notch develop induc pluripot stem cell ipsc -deriv
product may offer increas consist potenc convent cell therapi ipsc-deriv nk-cell
alreadi clinic ipsc-deriv t-cell remain elus goal reiter outperform pt
deliv earli sign clinic activ
tuesday aptos report earn provid updat clinic progress compani recent began dose
second cll patient open-label phase trial two cycl treatment scan show reduct tumor
burden evid clinic activ includ pronounc lymphocytosi common harmless side effect associ
btk inhibitor well-toler drug-rel advers reaction importantli evid
myelosuppress import consider aml patient compani intend begin test earli
dosing-escal proceed mg bid compani plan hold investor event review earli clinic
find trial reiter outperform pt
report ep vs estim consensu estim encourag
recent progress upcom catalyst includ enhanc pivot studi seladelpar pbc complet
enrol poc studi seladelpar nash fail show improv mri-pdff june interim studi
improv expect psc studi initi aasld present poster highlight
differ receptor select vs elafibranor ppar-/ agonist elafibranor nash result expect
view seladelpar well-differenti asset suffici fund cash balanc
report follow-up confer call
report adj ep compar opco/street estim
guidanc result exclud impair charg restructur cost loss
deriv rebrand applic track system off-set acquisition-rel conting
consider beat driven rebound top line strength rel broad-bas follow
quarter compani issu guidanc compar opco/street compani also
look long-term goal ebitda margin follow quarter tweak ep estim
updat seek proof-of-concept ipsc-nk
tuesday announc earn report recent progress follow ind clearanc septemb site initi
underway phase studi trial initi focu monotherapi treatment move
rituximab obinutuzumab combin similar design on-going phase protocol three ipsc-
deriv nk cell therapi clinic clinic data like dictat perform go forward unfortun
may wait clinic poc compani primari valu driver
expect updat although low expect given current track record adopt nk cell
therapi solid tumor reiter outperform pt
updat look ahead non-invas nash dynam
provid financi busi updat focus prepar potenti oca nash launch
encourag dialogu around build foundat support non-invas launch redefin nash
opportun advanc fibrosi manag expect outcom portion regener implement
differenti strategi optim nash pbc sustain long-term leadership fxr scienc expect
manag articul plan oca nash investor event held dec includ clinic
commerci compon support data regener market research physician payor updat
model result updat guidanc drive new pt
strong tug war outlook continu time
irhythm report rev y/i slightli higher consensu estim gross margin
roughli line consensu opex higher estim medicar
contribut overal rev quarter roughli consist past quarter store new store sale
compani continu point proprietari databas ecg data point data curat layer use
machin learn algorithm three-prong approach sale forc expans increas account penetr new
indic expect fuel irhythm growth
tuesday sere report result review recent progress see make-or-break year sere hing
data two pivot trial specif result ecospor trial recurr difficil infect
cdi expect previous eco-reset trial ulcer coliti uc
track deliv top-lin data previous given recent fatal attribut drug-resist coli fecal
microbiota transplant fmt highlight nejm believ spore-bas product like composit
defin altern like may repres safer altern unregul fmt recent debt financ
extend oper runway key mileston reiter outperform pt
review pipelin commerci execut continu pt
regeneron report sales/earn provid investor updat also provid
updat cemiplimab clinic develop timelin recent focu us oncolog anoth bud
pillar growth updat valid potenti best-in-class pipelin intern gener ophthalmolog
immunolog oncolog coupl commerci execut power eylea dupix line
consensu expect power y/i sale growth howev non-gaap opex still grew faster rate sale
q/q lead reduct non-gaap oper margin one area trail peer group updat
number reduc pt sector multipl compress stay bullish
updat highlight progress sever front
provid updat outlin progress toward initi studi biopsy-confirm nash patient
ind packag submit pend fda review nash ind includ addit chronic toxic
studi support long-term dose human previou data suggest us fda like comfort
preclin safeti requir expect studi protocol mirror previou trial base recent
fda guidanc nash clinic trial cover patient protocol also includ mri-pdff interim
readout like ind-en work x-ald start cash balanc expect cover key
readout updat model actual
continu progress
sale exceed our/street estim days-adjust constant-curr basi
sale grew cc day adjust one bill day hip drove out-performance versu estim
knee line think days-adjust rosa initi roll-out contribut versu estim
better sg leverag off-set lower gross margin lead slightli higher oper margin ep
us/street estimate higher sale reiter guidanc manag highlight progress sever front
quarter continu suppli stabil pivot increas manufactur effici sever sale driver ahead includ
strong rosa knee demand persona revision/cementless knee new spine launch invest special
review focu sharpen pegasu near pivot januari readout
apelli report result provid corpor updat clinic program focu slight
adjust guidanc top-lin data pegasu announc expect januari vs decemb
previous timelin updat caus much surpris us matter week month among compani
file updat compani priorit expans indic provid underscor thought
recognit leverag potenti achiev differenti clinic meaning benefit commerci viabl
therapeut area ahead present one indic friday updat
model quarter stay bullish
report soft bill execut concern linger
report result mostli consensu estim posit hire appear back target
follow shortfal accord manag suggest execut trend could start improv new
capac ramp howev bill soft miss street estim second time year rais execut
concern growth core market product materi slow bottom line believ great
vision good posit within midmarket custom engag opportun see better opportun elsewher
near-term given shortag buyer current market high-multipl softwar name like also
lumpi execut recent quarter maintain perform
solid execut advertis leverag impli traffic dynam
report solid beat strong domest aarsd y/i lead y/i outpac mau
healthi contribut new product manag rais high end adjusted-ebit guidanc higher
sale market leverag indic increas traffic effici across diversifi market channel also
maintain domest traffic edg revenu rose y/i strength uk lead
cost per lead declin expect pushback premium valuat believ internet
car marketplac leverag signific traffic advantag proprietari valuat technolog gain increment share
dealer budget lead potenti increas estim outperform pt
third straight quarter north american auto site growth site yoy report ebitda
line our/street estim compani continu perform well dealer
revenu high singl digit make meaning progress site dealer retent improv despit
slight revenu declin manag reiter guidanc call revenu ebitda
separ compani settl anoth lawsuit time nvsc maintain outperform
profit initi track achiev medium-term margin target
increas ebitda higher opex leverag maintain pt follow solid profit beat
ebitda street estim encourag origin y/i vs market growth
new commit fund sourc point lc abil remain resili potenti downturn
would expect margin surpass medium-term margin target higher market leverag monitor
deceler revenu impli guidanc appear driven profit initi lower fee higher-
grade mix shift trade ev/ebitda vs expect ebitda grow see market
underappreci lc scale abil weather difficult oper condit maintain outperform
model report strong finish strategi appear work rais pt
model report result better consensu estim posit includ acceler subscript
revenu growth good book commentari nice big deal commentari new up-sel improv busi
fundament healthi cash flow gener balanc oper incom guidanc impli margin
lower margin expans trend versu may take time investor gain comfort bottom line
believ manag strategi work good execut posit momentum busi experienc
like continu unab think visibl predict saa revenu improv
catalyz re-rat valuat multipl higher toward saa group averag reiter outperform rais pt
cloud
in-lin quarter revenu bottom extend militari contract major posit
boingo result solid revenu normal ep came better estim vs
vs respect help one-tim fee posit compani extend contract
forc militari give right build oper wireless tower base access fee da
revenu bright spot increas grow nearli annual exclud
non-recur access fee revenu contract amend activ level interest offic in-door connect use
wi-fi/cbr spectrum pick could long-term benefit maintain outperform rate
analyt collabor infrastructur softwar
address focu sale execut
report sale modestli ahead expect set revenue guidanc larg line expect albeit
last quarter reset level posit includ encourag step address product/competit gap steadi enterpris
engag on-going brisk larg deal activ yoy increas deal hire also pick
though back-end load contribut larg ep beat normal expect howev
bill defer metric disappoint vs expect comment sale productivity/engag highlight
full recoveri still multipl quarter away come away increment comfort competit posit
stay engag earli step realign compani sales/go-to-market effort maintain outperform adjust estim
reflect results/our perspect outlook
report strong earn revenu line ebitda modestli street howev investor focu
slow tinder sub q/q revenu y/i vs y/i believ tinder sub street estim
buy-sid expect tinder average sub y/i vs na y/
result consolid average sub y/i vs y/i arpu y/i ex fx tinder arpu
equival properti manag see growth tinder monet revenu guidanc
maintain high-teen y/i growth ebitda guid manag provid preliminari revenue/
ebitda guidanc mid-to-high teen vs street suggest margin line manag note
increment discretionari invest around new bet ebitda drag plu spin-off-rel expens
new bet show solid momentum hing download ytd vs last year okcupid india download
past year manag note plan focu hing monet well grow okcupid
select countri within middl east would like manag discuss market strategi address tinder growth
time around spin-off wednesday et call
plenti move part fiscal maintain outperform target
maintain outperform rate target peloton report strong result better annual guidanc new
public compani connect fit sub revenu growth exceed y/i subscrib engag y/
measur averag monthli workouts/sub fy guidanc exceed expect metric subscript
contribut margin guidanc impli q/q deceler caus new studio leas pre-launch product
german content consist y/i improv howev manag guid connect fit sub y/i
street acquir primari bike manufactur tonic speed product maintain high qualiti compani
success holiday period increas tread sale new bike market tactic impli ev/gp
report strong result revenu ep well estim even adjust higher
deconvers fee ep beat our/street estim despit drag higher tax rate higher
anticip higher deconvers fee boost ep organ revenu growth strong peer
quarter manag suggest quarterli sale result strong highlight five new core
custom win five in-hous outsourc decis direct perhap conserv affirm
guidanc revenu growth modest margin degrad maintain perform rate due valuat consider
note supplement note
smartphon ap shipment china continu fall say digitim research digitim
global semiconductor sale drop digitim
quick read ww set launch new product innov
market close tue nov perform-r ww report sep result updat guidanc
overal key subscrib trend ww continu stabil improv compani set launch new product
innov next week design excit re-engag potenti subscrib import new year sign-up
period beyond monitor ww close soon visit senior leadership compani
increasingli optimist success new product campaign support power market help reignit strong
subscrib expans brand
includ model updat follow nwl report remain encourag ceo ravi saligram addit
manag team improv financi execut cfo chri peterson leadership potenti
continu sluggish core sale growth valuat keep us sidelin base updat forecast share trade
ebitda forecast much remain radar
sustain growth resourc optim
sustain growth driver growth look sustain
miss top/bottom line consensu feder project time reiter guidanc base contract
revenu visibl preliminarili indic could see hsd sale ebitda growth record quarterli award
total backlog speak view increas custom demand sophist distribut energi solut support
energi resili sustain recent addit energi asset pipelin like fuel multi-year growth recur
ebitda/cf gener amrc manag renew credit exposur appear de-risk estim
see decade-long runway capit expertis renew natur ga meet sustain commit
util landfil ga owner mush custom estim thesi unchang maintain
outperform rate pt
sustain growth resourc optim
takeaway manag meet
commentari consist call reiter expect grow market increas
resili earn diversif manag note conserv stanc market dynam given
industri headwind relat uncertainti brexit timelin lack china domest stimulu clariti potenti local
oem consolid along inventori draw around us elect system architectur perspect see
continu extend leadership posit enjoy consolid attrit industri move
beyond given increas data improv accid rate y/i us part attribut
activ safeti applic expect custom demand increment margin expans oem offer
continu drive technolog adopt believ system solut posit compani sustain market share
gain potenti licens opportun
guid flattish organ growth slightli posit autom solut slightli neg manag
share conclus overal operational/portfolio/capit alloc review board februari investor
meet though share repurchas restructur upsw alreadi guid guidanc protocol
exclud restructur discret tax item render vs report higher restructur begun
project next coupl year target return gm
level today ebit like prior peak exclud bp restructur time
report adj ep vs our/consensu miss driven weaker expect revenu
segment lower anticip infrastructur margin infrastructur segment growth/profit impact
slower anticip recoveri resi construct volum us canada well lower inventori level
channel margin expect segment profit quarter exhibit
sale guid lsd muni lsd resi lsd natur ga msd adj ebitda growth impli
vs pre-report estim notabl walter energi tax liabil accrual reduc
manag expect matter fulli resolv calendar year-end
owe mostli soft heavy-duti truck well weak automot gener industri enpro
adjust ebitda miss our/street estim power system bright spot owe
healthi militari sale aftermarket strength reflect on-going weak truck automot
manag lower guidanc call adjust ebitda previous
adjust ebitda maintain outperform lower pt
first look strong ebitda execut debt reduct
expect modest posit reaction share strong execut quarter differenti oasi
peer face on-going infrastructur challeng oasi deliv strong earn print show compani abil
deliv growth face oper challeng williston basin peer compani show valu
infrastructur process asset net debt declin q/q support gener
asset sale mboe/d product impact delawar basin q/q growth mboe/d outpac
expect compani chang product guidanc wednesday call expect manag
address increas dd q/q highest level sinc
white deliv anoth disappoint quarterli print close deliv earnings/production/pr lag
expect infrastructur ga process continu problem white appear valid view
compani littl visibility/confid time well tie-in access natur ga process infrastructur
record-low realiz natur ga ngl point structur challeng face wiliiston basin oper
hope get color manag earn call navig issu could
play result consid guidanc provid releas worth note compani outpac
expect cash unit expens come expect capital-expenditure quarter
forecast signific chang guidanc broad well result foreman butt
sanish provid expect focu wednesday call
growth continu although incent incom slow patch
incent incom rel small portion total revenu comparison major privat equiti pe sponsor
still sizeabl lumpi past ten quarter incent incom account averag revenu
rang thu one need ph statist know one draw mani
conclus fact quarter averag write share
gener matter found littl pricey tast noth fy result suggest
compani knock strong long-term growth trajectori
slrc report nii bit estim comfort dividend
ninth consecut quarter compani out-earn dividend cumul come even
tradit cash flow lend bdc bread butter comprehens portfolio
fye quarter result like benefit unusu high prepay fee life scienc
vertic believ continu cover dividend comfort despit mark one new non-accru
pretti stabl roughli unchang past five year
stabl quarter asset qualiti continu excel
sun report net invest incom nii slightli estim cover
dividend given nii benefit incent fee waiver nii base
manag fee waiver core result near expect despit continu fee waiver still favor solar
platform approach lend busi manag focus effort asset-back specialti lend
busi strengthen sun risk/return profil number way given focu see compani
dividend yield premium indic strong asset qualiti franchis
dec cloud summit aw inventla vega nv
may biotech summit featur chemistri life process institutechicago
